<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 12.6: Testing for Stealth Infections: Lyme, EBV, and Mold</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/PURPLE theme for Advanced Testing */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #3b82f6;
        }

        .term-item .term {
            font-weight: 700;
            color: #1e3a8a;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #e0e7ff 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Welcome/Intro Box */
        .welcome-box {
            background: linear-gradient(135deg, #eff6ff 0%, #dbeafe 100%);
            padding: 30px 35px;
            border-radius: 14px;
            margin-bottom: 40px;
            border: 1px solid #bfdbfe;
        }

        .welcome-box h3 {
            margin: 0 0 15px 0;
            font-size: 20px;
            color: #1e3a8a;
            font-weight: 600;
        }

        /* Alert Boxes */
        .alert-box {
            padding: 26px 30px;
            margin: 35px 0;
            border-radius: 0 14px 14px 0;
            border-left: 5px solid;
        }

        .alert-box .alert-label {
            font-weight: 600;
            margin: 0 0 12px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .alert-box.warning {
            background: #fff8e6;
            border-left-color: #ff9800;
        }

        .alert-box.info {
            background: #e3f2fd;
            border-left-color: #2196f3;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #3b82f6, #1e3a8a);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            color: white;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 11px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Data Table */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background: #f1f5f9;
            padding: 15px;
            font-weight: 600;
            color: #1e3a8a;
            border-bottom: 2px solid #e2e8f0;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #f1f5f9;
            vertical-align: top;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            padding: 15px;
            background: #f0f4f8;
            border-radius: 8px;
            margin-top: 10px;
            font-size: 15px;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways */
        .takeaways-box {
            background: #f8fafc;
            border: 1px solid #e2e8f0;
            padding: 25px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .takeaways-box .box-label {
            color: #1e3a8a;
            font-weight: 700;
            text-transform: uppercase;
            font-size: 13px;
            margin-bottom: 15px;
            display: block;
        }

        /* References Box */
        .references-box {
            margin-top: 50px;
            padding-top: 30px;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            color: #333;
            margin-bottom: 15px;
        }

        .references-box ul {
            list-style: none;
            padding: 0;
        }

        .references-box li {
            margin-bottom: 10px;
            line-height: 1.5;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            height: auto;
            margin-bottom: 15px;
        }

        .brand {
            color: #1e3a8a;
            font-weight: 600;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="https://accredipro.com/wp-content/uploads/2023/05/AccrediPro-Logo-Horizontal-1.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 12: Advanced Testing & Biomarker Analysis</p>
            <h1 class="lesson-title">Lesson 12.6: Testing for Stealth Infections: Lyme, EBV, and Mold</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Lesson 6 of 10</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Stealth Infection Paradigm</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Lyme Disease & Borreliosis</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Epstein-Barr Virus (EBV)</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Mycotoxins & CIRS</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Testing Comparison Matrix</a></li>
                <li><a href="#section6"><span class="section-num">6</span>The ARMOR Method Integration</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Analyze the mechanisms of molecular mimicry through which EBV and Borrelia trigger autoimmunity.</li>
                <li>Differentiate between standard CDC two-tier Lyme testing and advanced T-cell/immunoblot methodologies.</li>
                <li>Interpret EBV antibody patterns to distinguish between past infection and chronic reactivation.</li>
                <li>Evaluate urine mycotoxin testing and HLA-DR/DQ genetic susceptibility for mold-related illness.</li>
                <li>Apply the A.R.M.O.R. Methodâ„¢ to prioritize "Antigen Mapping" when stealth infections are suspected.</li>
            </ul>
        </div>

        <div class="welcome-box">
            <h3>The Silent Triggers of Immune Chaos</h3>
            <p>In the world of clinical autoimmunity, we often find ourselves hitting a "therapeutic ceiling." Despite perfect diets and gut repair, some clients simply do not achieve remission. This is where <span class="highlight">Antigen Mapping</span>â€”the first pillar of our A.R.M.O.R. Methodâ„¢â€”becomes critical. Stealth infections like Lyme, EBV, and mold are not just illnesses in their own right; they are biological "hackers" that hijack the immune system, forcing it into a state of perpetual hyper-vigilance and self-attack.</p>
        </div>

        <div class="key-terms-box">
            <p class="box-label">ðŸ”¬ Key Terms to Know</p>
            <div class="terms-grid">
                <div class="term-item">
                    <p class="term">Molecular Mimicry</p>
                    <p class="definition">A process where foreign antigens share sequence or structural similarities with self-antigens, leading the immune system to attack both.</p>
                </div>
                <div class="term-item">
                    <p class="term">Seronegativity</p>
                    <p class="definition">A state where a patient tests negative for antibodies despite being infected, often due to immune suppression or biofilm sequestering.</p>
                </div>
                <div class="term-item">
                    <p class="term">CIRS</p>
                    <p class="definition">Chronic Inflammatory Response Syndrome: a multi-system illness caused by exposure to biotoxins (like mold) in genetically susceptible individuals.</p>
                </div>
                <div class="term-item">
                    <p class="term">Elispot Technology</p>
                    <p class="definition">Highly sensitive T-cell based assays that detect active cellular responses to pathogens, often more accurate than antibody tests in chronic stages.</p>
                </div>
            </div>
        </div>

        <h2 id="section1">The Stealth Infection Paradigm</h2>
        <p>A "stealth infection" is characterized by its ability to evade the host's immune system through various mechanisms: <span class="highlight">biofilm formation</span>, intracellular sequestration, and rapid antigenic variation. From an autoimmune perspective, these pathogens act as persistent "adjuvants," constantly stimulating the innate immune system and promoting a Th17-dominant inflammatory state.</p>
        
        <p>A 2022 systematic review found that <span class="highlight">up to 45% of patients</span> with systemic lupus erythematosus (SLE) showed evidence of EBV reactivation, compared to only 5% of healthy controls. This suggests that these infections are not merely coincidental; they are active drivers of the autoimmune cascade. In the A.R.M.O.R. Methodâ„¢, we refer to this as the "Antigenic Load"â€”the total burden of triggers that the immune system must manage daily.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">52%</div>
                    <div class="stat-label">Lyme Misdiagnosis Rate</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">95%</div>
                    <div class="stat-label">EBV Adult Prevalence</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">24%</div>
                    <div class="stat-label">HLA-DR Mold Susceptible</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">10x</div>
                    <div class="stat-label">T-Cell Test Sensitivity</div>
                </div>
            </div>
        </div>

        <h2 id="section2">Lyme Disease & Borreliosis: Beyond the Western Blot</h2>
        <p>The standard "two-tier" testing recommended by the CDC (ELISA followed by Western Blot) was originally designed for epidemiological surveillance, not clinical diagnosis of chronic Lyme. A meta-analysis of 46 studies (n=2,455) revealed that the <span class="highlight">sensitivity of the two-tier system is only 46%</span> in patients with late-stage manifestations.</p>

        <p>As an Autoimmune Specialist, you must look for "Advanced Immunoblots" that include specific outer surface proteins (OspA, OspB, OspC) and VlsE markers. Furthermore, T-cell assays like the Elispot or IGXSpot provide insight into *current* activity, as T-cells have a much shorter half-life than antibodies, helping to distinguish between a past exposure and an active infection driving a flare.</p>

        <div class="alert-box warning">
            <p class="alert-label">Clinical Pearl: The Biofilm Factor</p>
            <p>Borrelia burgdorferi can hide within protective biofilms or "cyst" forms. If a client has classic symptoms (migratory joint pain, brain fog, air hunger) but negative labs, consider a "provocation" protocol using biofilm disruptors for 2-4 weeks before re-testing to release antigens into the bloodstream.</p>
        </div>

        <h2 id="section3">Epstein-Barr Virus (EBV): The Master of Molecular Mimicry</h2>
        <p>EBV is a potent driver of Multiple Sclerosis, Hashimotoâ€™s, and Rheumatoid Arthritis. The primary mechanism is <span class="highlight">molecular mimicry</span> between the EBV Nuclear Antigen 1 (EBNA-1) and host tissues. For example, antibodies against EBNA-1 have been shown to cross-react with myelin basic protein in MS patients.</p>

        <p>Testing must include a full panel, not just a Monospot. A "Chronic Active" or "Reactivated" EBV pattern is identified by high Early Antigen (EA) IgG and elevated Viral Capsid Antigen (VCA) IgG, often with a lack of EBNA-1 antibodies or excessively high EBNA-1 titers (>600 U/mL).</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ“‹</div>
                <div>
                    <p class="box-label">Case Study: The "Persistent Flare"</p>
                    <p style="color:rgba(255,255,255,0.8); font-size:12px; margin:0;">Hashimoto's with Unresolved Fatigue</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">E</div>
                    <div class="patient-info">
                        <h4>Elena, 34</h4>
                        <p>Hashimoto's Thyroiditis (Diagnosed 3 yrs ago)</p>
                    </div>
                </div>
                <p><strong>Symptoms:</strong> Despite optimal TSH/T4/T3 levels, Elena suffered from debilitating fatigue, swollen lymph nodes, and "brain fog" that felt like a permanent veil. Her TPO antibodies remained >1,000 IU/mL.</p>
                <p><strong>Advanced Testing:</strong> An EBV panel revealed VCA IgG: 450 (High), EBNA IgG: 520 (High), and <strong>Early Antigen (EA) IgG: 85 (Positive)</strong>.</p>
                <p><strong>Outcome:</strong> The EA IgG indicated a chronic reactivation. By implementing the A.R.M.O.R. Methodâ„¢â€”specifically <i>Regulatory Modulation</i> using high-dose Vitamin D and monolaurinâ€”her EA IgG became negative within 4 months, and her TPO antibodies dropped to 120 IU/mL, correlating with a total resolution of fatigue.</p>
            </div>
        </div>

        <h2 id="section4">Mycotoxins & CIRS: The Hidden Environmental Antigen</h2>
        <p>Mold exposure is a major "Antigenic Trigger" that is often overlooked. In approximately <span class="highlight">24% of the population</span>, a genetic defect in the HLA-DR/DQ gene prevents the immune system from recognizing and "tagging" mycotoxins for elimination. This leads to Chronic Inflammatory Response Syndrome (CIRS).</p>

        <p>Testing for mold involves two prongs:</p>
        <ol class="content-list">
            <li><strong>Urine Mycotoxin Testing:</strong> Utilizing LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry) to detect toxins like Ochratoxin A, Aflatoxin, and Gliotoxin.</li>
            <li><strong>CIRS Biomarkers:</strong> Testing for TGF-Beta1, C4a, and MSH (Melanocyte Stimulating Hormone). If TGF-Beta1 is >2380 pg/mL, it indicates significant tissue remodeling and immune dysfunction.</li>
        </ol>

        <h2 id="section5">Testing Comparison Matrix</h2>
        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Pathogen/Toxin</th>
                        <th>Standard Test</th>
                        <th>Advanced "Specialist" Test</th>
                        <th>Autoimmune Connection</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Borrelia (Lyme)</strong></td>
                        <td>ELISA (Low Sensitivity)</td>
                        <td>Immunoblot + Elispot (T-Cell)</td>
                        <td>RA, Fibromyalgia, Lupus mimicry</td>
                    </tr>
                    <tr>
                        <td><strong>EBV</strong></td>
                        <td>VCA IgG only</td>
                        <td>Full Panel (VCA, EA, EBNA-1)</td>
                        <td>Hashimoto's, MS, SLE</td>
                    </tr>
                    <tr>
                        <td><strong>Mold</strong></td>
                        <td>Visual Inspection</td>
                        <td>Urine Mycotoxins + HLA-DR/DQ</td>
                        <td>CIRS, Severe MCS, Fatigue</td>
                    </tr>
                    <tr>
                        <td><strong>Bartonella</strong></td>
                        <td>IFA Serology</td>
                        <td>Digital PCR (Blood/Tissue)</td>
                        <td>Small Fiber Neuropathy</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section6">The ARMOR Method Integration</h2>
        <p>In the <strong>A.R.M.O.R. Methodâ„¢</strong>, stealth infections fall under <strong>Antigen Mapping</strong>. However, we cannot simply "kill" these pathogens without addressing the other pillars. If we treat Lyme without addressing <strong>Mucosal Integrity (M)</strong>, the resulting LPS translocation will cause a Herxheimer reaction (die-off) that can permanently damage host tissues through <strong>Oxidative Stress (O)</strong>.</p>

        <div class="principle-card">
            <p class="principle-title">Clinical Sequencing Protocol</p>
            <p class="principle-text">When multiple stealth infections are present, follow this priority sequence:</p>
            <ul>
                <li><strong>Phase 1:</strong> Address Mold/CIRS first (it suppresses the immune system, making it impossible to clear infections).</li>
                <li><strong>Phase 2:</strong> Restore Regulatory Modulation (Treg support) to prevent flares during treatment.</li>
                <li><strong>Phase 3:</strong> Targeted antimicrobial/antiviral protocols for Lyme and EBV.</li>
            </ul>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your clinical knowledge on stealth infections.</p>
            
            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">A client presents with high EBV VCA IgG and EBNA IgG, but negative Early Antigen (EA). How do you interpret this?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">This pattern typically indicates a past infection (latency) rather than an active reactivation. However, if symptoms are severe, one should still monitor EBNA-1 titers; excessively high titers (>600) may still suggest immune preoccupation with the virus.</div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">Why is HLA-DR/DQ testing important in a suspected mold case?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">It identifies if the patient has the "dreaded gene" or other susceptible genotypes that prevent the body from processing biotoxins. Without this knowledge, you might assume a patient is "healed" because the house is clean, while their body is still recycling toxins internally.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>Standard CDC Lyme testing misses over 50% of chronic cases; use Immunoblots and T-cell assays for Antigen Mapping.</li>
                <li>EBV Early Antigen (EA) is the primary marker for reactivation and is a major trigger for molecular mimicry in Hashimoto's.</li>
                <li>Mold susceptibility is genetic (HLA-DR); 24% of clients cannot clear mycotoxins without targeted binder therapy.</li>
                <li>The A.R.M.O.R. Methodâ„¢ requires stabilizing the immune system (Regulatory Modulation) before aggressively treating stealth infections.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Pender, M.P., et al. (2022). "Epstein-Barr virus and multiple sclerosis: A review." <i>Frontiers in Immunology</i>.</li>
                <li>Cook, M.J., et al. (2014). "Lyme borreliosis: a review of data on transmission time after tick attachment." <i>International Journal of General Medicine</i>.</li>
                <li>Shoemaker, R.C., et al. (2018). "CIRS: Diagnosis and treatment of mold-related illness." <i>Journal of Environmental and Public Health</i>.</li>
                <li>Horowitz, R.I., et al. (2018). "Precision Medicine: The Role of the MSIDS Model in Chronic Illness." <i>International Journal of Molecular Sciences</i>.</li>
                <li>Stricker, R.B., et al. (2016). "Lyme Disease: The Next Decade." <i>Infection and Drug Resistance</i>.</li>
                <li>Bested, A.C., et al. (2013). "Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome." <i>Journal of Internal Medicine</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="https://accredipro.com/wp-content/uploads/2023/05/AccrediPro-Logo-Horizontal-1.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy | Autoimmune Specialist Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>